Business · 30/08/1994Updated: 10/18/2026 · 1 min read
FDA Determines Regulatory Review Period for Kytril Patent Extension
Summary
The US Food and Drug Administration (FDA) has officially confirmed the regulatory review period for the patent extension of Kytril, a human drug product, following a submission to the US Department of Commerce's Commissioner of Patents and Trademarks.
Original source language: Federal Register — Health and Human ServicesOpen original release →